Despite their nearness to death, a sizeable proportion of advanced cancer patients remain unaware of basic information about their illness or its treatment, according to Holly Prigerson, Ph.D. Read more
The rate at which genetically mutated cancer cells grow may help explain why patients with CLL develop resistance to ibrutinib, according to Dan Landau, M.D., Ph.D. Read more
Ellen Ritchie, M.D., discusses the current best practices in the management of myelodysplastic syndromes and how the latest research is likely to impact the field. Read more